Francisco Sanchez-Vega

Assistant Attending
Epidemiology & Biostatistics
Directory
Epidemiology
Biostatistics
Health Outcomes
MSK Computational Oncology Department & Staff
Administrative Resources
Career Opportunities
Educational Opportunities
Departmental Newsletter

Francisco Sanchez-Vega

Assistant Attending
Share
Share
Francisco Sanchez-Vega

Office Phone

646-608-7530

Email

[email protected]

Education

Johns Hopkins University

Francisco Sanchez-Vega is an Assistant Attending Computational Oncologist in the Colorectal Cancer Service of the Department of Surgery, and is affiliated with Computational Oncology in the Department of Epidemiology and Biostatistics. His research focuses on translational applications of machine learning, statistical modeling and computational methods to the field of cancer genomics and precision oncology. Dr. Sanchez-Vega’s doctoral research work addressed the challenge of learning graphical models to efficiently describe high-dimensional, multivariate probability distributions within the context of small-sample regimes. During his postdoctoral experience at the National Human Genome Research Institute, he investigated patterns of aberrant DNA methylation in cancer and identified novel epigenetic biomarkers that could be used for early detection through non-invasive screening tests. Since his arrival at MSK in 2015, he has worked in a wide variety of translational genomic projects. Notable examples include the analysis of molecular determinants of response to anti-HER2 targeted therapies in patients with ERBB2 positive esophagogastric adenocarcinomas, understanding the interplay between mutational burden and response to immune checkpoint inhibitors in lung adenocarcinoma and characterizing the genomic bases of organ-specific metastasis. Dr. Sanchez-Vega was also actively involved and played leadership roles in several of the final marker papers from The Cancer Genome Atlas (TCGA) and the TCGA Pan-Cancer Atlas initiative, where he was one of the driving forces behind the flagship study that characterized somatic alterations in 10 canonical oncogenic signaling pathways in 9,125 tumors from 33 different cancer types.

Publications

  1. Schvartzman JM, Forsyth G, Walch H, Chatila W, Taglialatela A, Lee BJ, Zhu X, Gershik S, Cimino FV, Santella A, Menghrajani K, Ciccia A, Koche R, Sánchez-Vega F, Zha S, Thompson CB. Oncogenic IDH mutations increase heterochromatin-related replication stress without impacting homologous recombination. Mol Cell. 2023 Jul 6;83(13):2347-2356.e8. doi: 10.1016/j.molcel.2023.05.026. Epub 2023 Jun 12. PMID: 37311462.
  2. Omer DM, Thompson HM, Verheij FS, Yuval JB, Rosen R, Beets NRA, Luthra A, Romesser PB, Paty PB, Garcia-Aguilar J, Sanchez-Vega F. Rectal Cancer after Prostate Radiation: A Complex and Controversial Disease. Cancers (Basel). 2023 Apr 9;15(8):2214. doi: 10.3390/cancers15082214. PMID: 37190143; PMCID: PMC10136617.
  3. Lengel HB, Mastrogiacomo B, Connolly JG, Tan KS, Liu Y, Fick CN, Dunne EG, He D, Lankadasari MB, Satravada BA, Sun Y, Kundra R, Fong C, Smith S, Riely GJ, Rudin CM, Gomez DR, Solit DB, Berger MF, Li BT, Mayo MW, Matei I, Lyden DC, Adusumilli PS, Schultz N, Sanchez-Vega F, Jones DR. Genomic mapping of metastatic organotropism in lung adenocarcinoma. Cancer Cell. 2023 May 8;41(5):970-985.e3. doi: 10.1016/j.ccell.2023.03.018. Epub 2023 Apr 20. PMID: 37084736; PMCID: PMC10391526.
  4. Karasaki T, Moore DA, Veeriah S, Naceur-Lombardelli C, Toncheva A, Magno N, Ward S, Bakir MA, Watkins TBK, Grigoriadis K, Huebner A, Hill MS, Frankell AM, Abbosh C, Puttick C, Zhai H, Gimeno-Valiente F, Saghafinia S, Kanu N, Dietzen M, Pich O, Lim EL, Martínez-Ruiz C, Black JRM, Biswas D, Campbell BB, Lee C, Colliver E, Enfield KSS, Hessey S, Hiley CT, Zaccaria S, Litchfield K, Birkbak NJ, Cadieux EL, Demeulemeester J, Van Loo P, Adusumilli PS, Tan KS, Cheema W, Sanchez-Vega F, Jones DR, Rekhtman N, Travis WD, Hackshaw A, Marafioti T, Salgado R, Le Quesne J, Nicholson AG; TRACERx Consortium; McGranahan N, Swanton C, Jamal-Hanjani M. Evolutionary characterization of lung adenocarcinoma morphology in TRACERx. Nat Med. 2023 Apr;29(4):833-845. doi: 10.1038/s41591-023-02230-w. Epub 2023 Apr 12. PMID: 37045996; PMCID: PMC7614478.
  5. Liu Y, Chudgar N, Mastrogiacomo B, He D, Lankadasari MB, Bapat S, Jones GD, Sanchez-Vega F, Tan KS, Schultz N, Mukherjee S, Offit K, Bao Y, Bott MJ, Rekhtman N, Adusumilli PS, Li BT, Mayo MW, Jones DR. A germline SNP in BRMS1 predisposes patients with lung adenocarcinoma to metastasis and can be ameliorated by targeting c-fos. Sci Transl Med. 2022 Oct 5;14(665):eabo1050. doi: 10.1126/scitranslmed.abo1050. Epub 2022 Oct 5. PMID: 36197962; PMCID: PMC9926934.

 

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Francisco Sanchez-Vega discloses the following relationships and financial interests:

No disclosures meeting criteria for time period


The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].


View all disclosures

Related topics: